Songsivilai S, Lachmann P J
Molecular Immunopathology Unit, Medical Research Council Centre, Cambridge, England.
Clin Exp Immunol. 1990 Mar;79(3):315-21. doi: 10.1111/j.1365-2249.1990.tb08089.x.
Antibodies with two distinct binding specificities have great potential for a wide range of clinical applications as targeting agents for in vitro and in vivo immunodiagnosis and therapy, and for improving immunoassays. They have shown great promise for targeting cytotoxic effector cells, delivering radionuclides, toxins or cytotoxic drugs to specific targets, particularly tumour cells. We discuss potential applications of bispecific antibodies, the theoretical basis and problems associated with their production and purification, cell fusion and chemical conjugation techniques, and propose a new manufacturing strategy by genetic engineering. This approach has enormous potential applications for producing tailor-made bispecific antibodies, and will enable widespread clinical uses of these antibodies both for diagnostic purposes and therapy.
具有两种不同结合特异性的抗体作为体外和体内免疫诊断及治疗的靶向剂，以及用于改进免疫测定，在广泛的临床应用中具有巨大潜力。它们在靶向细胞毒性效应细胞、将放射性核素、毒素或细胞毒性药物递送至特定靶点，尤其是肿瘤细胞方面已显示出巨大前景。我们讨论了双特异性抗体的潜在应用、与其生产和纯化相关的理论基础及问题、细胞融合和化学偶联技术，并提出了一种通过基因工程的新制造策略。这种方法在生产定制双特异性抗体方面具有巨大的潜在应用，并将使这些抗体能够广泛用于临床诊断和治疗。
